The aggregation of a-synuclein (aSyn) is a neuropathologic hallmark of Parkinson's disease and other synucleinopathies. In Lewy bodies, aSyn is extensively phosphorylated, predominantly at serine 129 (S129). Recent studies in yeast have shown that, at toxic levels, aSyn disrupts Rab homeostasis, causing an initial endoplasmic reticulum-to-Golgi block that precedes a generalized trafficking collapse. However, whether aSyn phosphorylation modulates trafficking defects has not been evaluated. Here, we show that constitutive expression of aSyn in yeast impairs late-exocytic, early-endocytic and/or recycling trafficking. Although members of the casein kinase I (CKI) family phosphorylate aSyn at S129, they attenuate aSyn toxicity and trafficking defects by an S129 phosphorylation-independent mechanism. Surprisingly, phosphorylation of S129 modulates aSyn toxicity and trafficking defects in a manner strictly determined by genetic background. Abnormal endosome morphology, increased levels of the endosome marker Rab5 and co-localization of mammalian CKI with aSyn aggregates are observed in brain sections from aSyn-overexpressing mice and human synucleinopathies. Our results contribute to evidence that suggests aSyn-induced defects in endocytosis, exocytosis and/or recycling of vesicles involved in these cellular processes might contribute to the pathogenesis of synucleinopathies.
INTRODUCTION
Synucleinopathies comprise a subset of neurodegenerative disorders characterized by the accumulation of cytoplasmic inclusions, or Lewy bodies (LBs), that contain the protein a-synuclein (aSyn) in selected populations of neurons [Parkinson's disease (PD) and dementia with Lewy bodies (DLB)] or glia [multiple system atrophy (MSA)]. Although the etiology of these disorders is unknown, the discovery of mutations in the aSyn gene (SNCA) that cause PD implicates aSyn in the pathogenesis of synucleinopathies (1) .
The precise cellular function of aSyn is unclear. aSyn is a pre-synaptic protein that stimulates the formation of synaptic vesicles and neuronal transmission in vitro and in vivo (2 -5) . Importantly, the discovery that multiplications of the aSyn locus cause PD suggests that neurotoxicity is a quantitative trait of aSyn (6) . Therefore, overexpression of aSyn has been widely used to study the molecular mechanisms of disease pathogenesis in a variety of model systems. In addition to other phenotypes, overexpression of aSyn appears to disrupt vesicular transport in cell-based and in vitro models, and in patients with PD (7 -11) . Yeast has proven useful as model to reconstitute aSyn dose-dependent cellular toxicity and vesicular transport defects. aSyn was shown to block ER-to-Golgi transport (12) and other intracellular trafficking pathways (13, 14) at toxic concentrations. These trafficking * To whom correspondence should be addressed. Tel: +1 4157342515; Fax: +1 4153550824; Email: pmuchowski@gladstone.ucsf.edu # The Author 2012. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com failures correlate with an accumulation of intracellular vesicles (13, 15) . Interestingly, aSyn toxicity in yeast and other model organisms can be modulated by manipulating the expression of genes involved in vesicular trafficking (12, (16) (17) (18) (19) (20) .
Posttranslational modifications of aSyn in vivo may play an important role in the pathogenesis of PD and other synucleinopathies. The most abundant modification of aSyn in LBs is the phosphorylation of serine 129 (S129) (21, 22) . This residue is located within a casein kinase (CK) consensus recognition site and is phosphorylated by yeast and mammalian CKs (14, (22) (23) (24) and other kinases (25) (26) (27) (28) in cellular and animal models. However, the relevance of S129 phosphorylation for pathogenesis remains controversial. Discordant studies in rats and Drosophila argue for protective, innocuous and detrimental effects of phosphorylation on neurodegeneration (29 -32) . Moreover, whether phosphorylation influences aSyn-induced intracellular trafficking defects has not been evaluated.
In this study, we show that late-exocytic, early-endocytic and/or recycling transport of plasma membrane (PM) proteins is disrupted by constitutive expression of aSyn in yeast. Yeast casein kinase 1 (Yck1) attenuates this defect by a phosphorylation-independent mechanism. However, blocking aSyn phosphorylation dramatically enhances aSyn toxicity and trafficking defects in a strain-specific manner in yeast, suggesting that genetic context determines the sensitivity to changes in the phosphorylation state of aSyn. We also report early endosome (EE) alterations and co-localization of mammalian CKId with aSyn-positive inclusions in mouse models and human synucleinopathy brains, providing evidence that endosome anomalies and CKId sequestration may contribute to the pathogenesis of synucleinopathies.
RESULTS

Overexpression of aSyn causes vesicles to accumulate in yeast
Wild-type (WT) aSyn-GFP ectopically expressed in yeast from the galactose-inducible promoter of the GAL1 gene accumulates in intracellular deposits that were initially described as inclusions (33) . The earliest inclusions form at 3.5 h of induction in the cell periphery and subsequently spread toward the cell interior (13) . Immuno-electron microscopy (IEM) studies revealed that the inclusions observed by fluorescence microscopy are composed of aSyn-positive clusters of vesicles (13, 15) . To further investigate the composition of these clusters, we examined the ultrastructure and the subcellular localization of aSyn by IEM over time in yeast expressing aSyn-GFP by the GAL1 promoter. Within the first 4 h of induction, aSyn-GFP immunoreactivity was almost exclusively observed at the PM (data not shown). At 6 h, we observed small clusters of vesicles in the vicinity of the PM (Supplementary Material, Fig. S1A and B). The vesicles were homogeneous in size ( 20-40 nm in diameter), morphology and electron density, suggesting a common origin. At 12 h, the clusters were enlarged, and their vesicular content became heterogeneous in morphology and size (up to 100 nm in diameter), consistent with multiple origins of vesicles due to a widespread trafficking defect as reported (13) Fig. S1C and D) . Notably, aSyn-GFP immunoreactivity was detected on the surface of the vesicles at 6 and 12 h, in agreement with previous reports showing that the aSyn inclusions observed by fluorescence microscopy correspond to these clusters of aSyn-positive vesicles.
Constitutive aSyn expression disrupts late-exocytic, early-endocytic and/or recycling trafficking in yeast Although the Lindquist group initially showed that aSyn inclusions co-localize with Ypt1, an endoplasmic reticulum (ER)-to-Golgi trafficking marker (12) , a follow-up study by the same group showed co-localization with diverse trafficking markers, including Ypt31 (late Golgi), Sec4 (secretory vesicles-to-PM), Ypt6 (endosome-to-Golgi), Vps21 and Ypt52 [EE-to-late endosome (LE)] and Ypt7 (LE-to-vacuole), suggesting that aSyn may disrupt multiple intracellular trafficking routes in yeast (13) . To investigate the precise origin of vesicles that accumulate after aSyn expression in yeast, we evaluated the effect of constitutively expressing untagged aSyn from a glycerol-3-phosphate dehydrogenase (GPD1) promoter in a 2 mm plasmid on the steady-state localization of a series of GFP-tagged protein markers for different intracellular trafficking pathways (34) (35) (36) (Fig. 1A) . GFP-Snc1, a transmembrane exocytic SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor), is targeted to the PM through the secretory pathway and subsequently recycled to the PM via EEs and the Golgi. Ste2-GFP, the transmembrane a-factor pheromone receptor, and GFP-Snc1-Sso1, an engineered variant of GFP-Snc1 containing a transmembrane domain of the SNARE Sso1, are targeted to the PM through the secretory pathway and, subsequently, after endocytosis, to the vacuolar lumen via EE and LEs. The SNARE GFP-Pep12 is targeted to the membrane of the prevacuolar complex (PVC) via the carboxypeptidase Y (CPY) biosynthetic pathway (ER to Golgi to PVC/LE to vacuole). The transmembrane proteins GFP-Phm5 and Sna3-GFP are targeted to the vacuolar lumen via the CPY pathway by ubiquitin-dependent and -independent mechanisms, respectively. GFP-Nyv1-Snc1, an engineered variant of the SNARE Nyv1 containing the transmembrane domain of Snc1, is targeted to the vacuole membrane via the alkaline phosphatase (ALP) pathway (ER to Golgi to vacuole).
To quantitatively assess the effect of aSyn on trafficking, we counted the percentage of cells that exhibit a mislocalization phenotype, considered as any anomaly in the localization pattern of a trafficking marker that differs from the pattern displayed by the majority of cells that do not express aSyn. Constitutive expression of untagged aSyn from the GPD1 promoter selectively prevented the proper targeting of GFP-Snc1 to the PM and of GFP-Snc1-Sso1 and Ste2-GFP to the vacuole lumen in 50-85% of cells, but not of GFP-Pep12 and GFP-Nyv1-Snc1 to the vacuole membrane or GFP-Phm5 and Sna3-GFP to the vacuole lumen ( Fig. 1B  and C) . The trafficking routes that are unique to the protein markers perturbed by untagged aSyn include Golgi-to-PM, PM-to-endosome and endosome-to-Golgi. These observations suggest that, at the steady-state expression levels achieved by the GPD1 promoter, untagged aSyn impairs the delivery of proteins to the PM from the Golgi and/or their subsequent Human Molecular Genetics, 2012, Vol. 21, No. 11 2433 endocytic and recycling trafficking. In contrast, other markers that use the ER-to-Golgi pathway but bypass the PM (GFP-Pep12, GFP-Phm5, Sna3-GFP and GFP-Nyv1-Snc1) do not exhibit localization defects in aSyn-expressing cells, suggesting that ER-to-Golgi trafficking is not impaired. We next analyzed the subcellular distribution of aSyn-GFP and the exocytic SNARE Snc1 by co-IEM (Fig. 2) . Consistent with the fluorescence microscopy studies, Snc1 immunoreactivity was detected in the aSyn-GFP-positive vesicular clusters, confirming anomalies in PM delivery, endocytic and/or recycling trafficking of Snc1. As aSyn has been reported to block the delivery of the dye FM 4-64 to the vacuole, but not its uptake (33), we propose that aSyn impairs postendocytic and/or recycling trafficking that follows vesicle budding from the PM (Fig. 1A) , at least at early stages after expression.
To gain further insights in the trafficking steps disrupted by aSyn, we investigated the subcellular distribution of GFPSnc1-Sso1 and the dye FM 4-64 in two subsets of yeast trafficking mutants (Supplementary Material, Fig. S2A ): first, in loss-of-function deletion mutants defective in intra-Golgi (ypt31D), endocytic (end3D, ypt51D), recycling (ypt31D), endosome-to-Golgi (vps35D) and endosome-to-vacuole (vps23D, did3D) transport, endosome and vacuole homotypic fusion (ypt7D) and actin remodeling (sac6D); second, in temperature-sensitive secretory mutants defective in ER-to-Golgi (sec7-4, sec18-1), intra-Golgi (sec7-4) and Golgi-to-PM (sec1-1) transport at permissive [room temperature (RT)] and non-permissive (378C) temperatures. Among all of the mutants studied, did3D and vps23D appear to most closely resemble the mislocalization pattern of GFP-Snc1-Sso1 caused by aSyn, suggesting a late-endocytic defect (Supplementary Material, Fig. S2B and C) . However, the mislocalization phenotype in aSyn-expressing cells seems to rather be unique, suggesting that multiple trafficking steps are affected, in agreement with a previous study (13) .
Yck1 attenuates aSyn-induced toxicity and trafficking defects through an S129 phosphorylation-independent mechanism There is increasing evidence that aSyn disrupts endocytic trafficking. For example, in yeast aSyn overexpression perturbs the subcellular distribution of the endocytic tracker FM 4-64 (33) and diverse endocytic protein markers (13) . The endocytic pathway modulates aSyn toxicity in Caenorhabditis elegans (17) . Therefore, we reasoned that genes that regulate endocytosis might also modify aSyn-induced growth defects and vesicle accumulation in yeast. To test this hypothesis, we assessed whether Yck1 and Yck2, two functionally redundant PM-associated members of the CKI protein family that promote the endocytosis of PM proteins (37, 38) , modulate 
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Human Molecular Genetics, 2012, Vol. 21, No. 11 aSyn toxicity. For these studies, we generated a yeast strain carrying two stably integrated copies of the human aSyn gene fused to GFP under the control of the GAL1 inducible promoter (which allows to control for gene-specific effects in non-inducing conditions) in the BY4741 strain ( Table 1) . As positive and negative controls, we deleted the genes TLG2, a known aSyn toxicity modifier encoding a SNARE required for the targeting of Yck2 to the PM (20, 39) , and SPO14, a gene encoding a yeast phospholipase D that does not modify aSyn toxicity (40) , respectively. In contrast to a previous study (14) , we found that deletion of YCK1 and YCK2 genes significantly increased the growth defect caused by aSyn-GFP ( Fig. 3A and Supplementary Material, Fig. S3 ).
To confirm these genetic interactions, we reasoned that pharmacologic inhibition of CKI activity in yeast expressing aSyn should phenocopy the yck1D or yck2D alleles, and this effect should be more dramatic in yeast lacking either one of the two functionally redundant enzymes. Therefore, we tested the effect of the CKI-specific inhibitor D4476 on the viability of cells expressing aSyn-GFP from two genomic loci. To make cells more sensitive to the compound, we knocked out the multidrug resistance gene PDR1 in all the strains tested. Although YCK1 or YCK2 are not individually essential for cell growth, deletion of both genes results in growth arrest. As expected, the CKI-specific inhibitor D4476 decreased yeast growth in a concentration-dependent manner (Supplementary Material, Fig. S4 ). Notably, this effect was more pronounced in cells expressing aSyn-GFP, and was significantly increased in cells lacking one of the two redundant enzymes (Supplementary Material, Fig. S4 ), suggesting that CKI activity counteracts the detrimental effects of aSyn overload.
To determine whether the increase in growth inhibition caused by the loss of CKI function correlates with increased trafficking defects, we studied the localization of mCherrytagged Snc1-Sso1 in WT and yck1D cells carrying two or zero integrated copies of the galactose-inducible aSyn-GFP gene. In cells not expressing aSyn-GFP, mCherry-Snc1-Sso1 is correctly delivered to the vacuolar lumen (Fig. 3B ). In contrast, expression of aSyn-GFP prevented the proper targeting of mCherry-Snc1-Sso1 in 30% of WT cells ( Fig. 3B and  C) . Note that the defect in these cells is less marked than in cells constitutively expressing untagged aSyn from a 2 mm plasmid, where 75% of cells are affected (Fig. 1C) . However, deletion of YCK1 did not aggravate this phenotype ( Fig. 3B and C) , indicating that the enhancement of growth defects by the yck1D mutation is not associated with an enhancement of endocytic trafficking defects.
Next, we investigated the ability of YCK1 to reverse aSyn-induced toxicity and trafficking defects ( Fig. 3D and E). We observed that YCK1 overexpression attenuates the growth defect caused by two copies of the aSyn-GFP gene in WT and yck1D cells. In addition, in contrast to the absence of trafficking defect enhancement upon deletion of YCK1, overexpression of YCK1 significantly reduced the percentage of cells showing abnormal localization of GFP-Snc1-Sso1 in cells constitutively expressing untagged aSyn (Fig. 3E) . Interestingly, Ypt1, a Rab GTPase that also suppresses untagged aSyn toxicity (12), decreased mislocalization of GFP-Snc1-Sso1 to the same extent. These results suggest that Yck1 and Ypt1 may alleviate aSyn toxicity, at least in part, by directly promoting PM endocytosis.
aSyn contains a consensus CKI phosphorylation site on S129 that is phosphorylated by yeast and mammalian CKI in vitro and in vivo (14, 24) . To assess whether aSyn is phosphorylated at S129 in yeast, we monitored the levels of total and phosphorylated aSyn-GFP (pS129) over time in WT cells carrying two copies of the aSyn-GFP gene under the control of the GAL1 promoter. Both aSyn and its phosphorylated form were detected after 1 h of inducing aSyn-GFP expression, indicating that aSyn is rapidly phosphorylated in yeast (Fig. 3F) . To test whether CKI modulates directly or indirectly the phosphorylation of aSyn at S129 in our model, we compared the relative levels of pS129 in the WT, yck1D and yck2D strains after 1 h of induction. The spo14D strain was included as negative control. As shown previously (14), we observed a modest ( 30%) decrease in the relative levels of pS129 in the yck1D and yck2D mutants compared with the WT strain ( Fig. 3G and H) , confirming that CKI contributes partially to the phosphorylation of S129.
To determine whether the attenuation of growth and trafficking defects by Yck1 is mediated by direct phosphorylation of aSyn, we measured the levels of pS129 in WT and yck1D cells transformed with a plasmid for the overexpression of YCK1 or the corresponding empty vector at 5.5 and 11 h of induction (Fig. 3I ). As control, we treated cells with a combination of the phosphatase inhibitors (PI) okadaic acid and activated Na 3 VO 4 . YCK1 overexpression did not increase aSyn phosphorylation in either WT or yck1D cells, suggesting that the attenuation of toxicity and trafficking defects by YCK1 is not mediated by direct phosphorylation of aSyn at S129, but rather through the phosphorylation of other targets. Cells were grown to the logarithmic phase (OD 600 ≈ 0.8) in raffinose-containing media and expression of aSyn was induced with galactose. Aliquots were collected at the indicated times and levels of phosphorylated (pS129) and total aSyn were analyzed by western blot. The soluble fraction is shown. The earliest aSyn was detected after 1 h of induction. (G) Deletion of YCK1 or YCK2 reduces aSyn phosphorylation modestly. The indicated strains were induced for 1 h and analyzed by western blot as described in (F). (H) Quantification of the S129 phosphorylation levels was estimated as the ratio of the band densities of phosphorylated relative to total aSyn from (G). (I) Overexpression of YCK1 does not increase aSyn phosphorylation at S129. WT or yck1D cells containing two copies (2c) or no copies (0c) of the aSyn-GFP gene in the BY4741 genetic background and transformed with a plasmid for the overexpression of YCK1 or the corresponding empty vector were grown to the logarithmic phase in raffinose-containing medium and induced with galactose. Aliquots were collected at the indicated times for western blot analysis. The indicated cultures were treated with the PI okadaic acid and activated Na 3 VO 4 for 15 min before being collected. Error bars represent standard deviations from three experiments in (A), (C), (D) and (E) and two experiments in (H). * P , 0.05; * * P , 0.01; * * * P , 0.001; (A, C, D and E) Student's t-test.
Phosphorylation regulates the toxicity and trafficking defects caused by aSyn in a genetic context-dependent manner
The role of S129 phosphorylation in disease pathogenesis is unclear, as contradictory results have been published in different models (29 -32,41,42) . To investigate the effect of S129 phosphorylation on aSyn-induced toxicity and trafficking defects in yeast, we generated strains that stably express WT aSyn-GFP or the phosphorylation mutants S129A-GFP or S129E-GFP from one or two genomic loci in the BY4741 strain background ( Table 1) . As expected, aSyn-GFP reduced cell growth in a dose-dependent manner (Fig. 4A) . However, replacement of S129 by A or E did not alter aSyn-GFP toxicity or expression levels ( Fig. 4A and B). These results suggest that phosphorylation at S129 does not modulate aSyn toxicity in the BY4741 strain background (although phosphorylation of other targets by Yck1 and Yck2 modulates aSyn toxicity as shown before). However, since the S129 phosphorylation status appears to govern aSyn neurotoxicity in fly and rat models (31,43), but not in two other models (29, 32) , we reasoned that variations in the genetic background of the models might account for the differential sensitivity of cells to the aSyn phosphorylation status.
To test this hypothesis, we generated strains that stably express WT aSyn-GFP or the phosphorylation mutants S129A-GFP or S129E-GFP from one or two genomic loci in the W303-1A genetic background (Table 1) . This strain carries a mutation in the YBP1 gene that increases its sensitivity to oxidative stress (44), a known mechanism of aSyn toxicity (45) . Whereas one copy of any of the three aSyn-GFP alleles had no impact on yeast growth, two copies were detrimental in an allele-specific manner (Fig. 4C) . Although the S129A mutation, which prevents phosphorylation, caused a dramatic increase in the growth defect caused by WT aSyn-GFP, the S129E-GFP mutation, which mimics phosphorylation, had no effect, suggesting that preventing phosphorylation enhances aSyn toxicity in the W303-1A strain background. Interestingly, the S129A-GFP mutation caused a significant 6-fold increase in the percentage of cells with aSyn-GFP inclusions in comparison with WT aSyn-GFP without altering expression levels ( Fig. 4D-F) , suggesting that blocking phosphorylation of S129 enhances trafficking defects caused by aSyn-GFP on the W303-1A genetic background.
To confirm this hypothesis, we studied the trafficking of the dye FM 4-64 in the strains with two copies of the WT aSyn-GFP gene, or the S129A-GFP and S129E-GFP mutations in the W303-1A background. As reported previously (33) , WT aSyn-GFP impaired the delivery of the dye to the vacuolar membrane ( Fig. 4G and H) . The S129A-GFP mutation significantly enhanced this defect, indicating that the enhancement of toxicity correlates with increased trafficking defects. Importantly, these defects were typically observed only in cells with aSyn inclusions (Fig. 4I) , regardless of the aSyn variant expressed, confirming that the formation of inclusions is an indication of underlying trafficking defects and suggesting a molecular link between phosphorylation and trafficking.
To verify whether the modulation of aSyn toxicity by Yck1 observed in the BY4741-derived strain is mediated by S129 phosphorylation or an independent mechanism, we deleted or overexpressed YCK1 in strains expressing two copies of the WT aSyn-GFP gene, or the S129A-GFP and S129E-GFP mutations in the W303-1A background. Unexpectedly, either deletion or overexpression of YCK1 did not alter the growth defect of these strains, whether expressing WT aSyn-GFP or the S129-GFP mutations (Fig. 4J ). These observations demonstrate that the genetic modification of a toxic phenotype is profoundly influenced by the genetic background and may help explain paradoxical observations reported in different models of aSyn toxicity.
Evidence of endosome anomalies and CKId mislocalization in aSyn transgenic mice and in synucleinopathy brains
To determine whether defects in early-endocytic trafficking are a conserved pathologic feature of synucleinopathies, we studied the subcellular localization of the EE protein marker Rab5 in brain tissues from a transgenic (tg) mouse model of synucleinopathy (46) and human DLB/PD. In tg mice, overexpression of human aSyn results in the formation of aSyn-positive inclusion-like structures in the neocortex, hippocampus and substantia nigra (SN) by 2 months of age (46) . In non-tg mice, Rab5 labeled discrete punctuate endosomes in the cytosol of cortical neurons at 6 months of age, whereas aSyn stained discrete puncta in the cell periphery. However, in tg animals, Rab5 labeled abnormally swollen endosomes in neurons that contained aSyn-positive intracellular inclusions (Fig. 5) . Interestingly, the swollen endosomes co-localized with small granular aggregates of aSyn, but were excluded from large Lewy-body-like inclusions. Similarly, in cortical sections of human control subjects, Rab5 and aSyn exhibited a punctuate pattern that rarely co-localized. However, in human DLB/PD cases, Rab5 stained abnormal endosomal compartments that co-localized with aSyn granular aggregates but not with LBs. Although the nature of the enlarged Rab5-positive endosomes is unknown and they may not be equivalent to the accumulation of vesicles observed in yeast-overexpressing aSyn, the presence of these abnormal endosomes suggests that dysfunction of the endocytic pathway may occur in aSyn tg mice.
To examine the early-endocytic trafficking machinery in pathologic states in vivo, we analyzed by western blot the levels of Rab5 and two other EE markers, Rab4 and EEA1, in the aSyn tg mice and in a tg mouse model of Alzheimer's disease (AD), a non-strict form of synucleinopathy in which a processed fragment of aSyn deposits in extracellular amyloid plaques. In this model, expression of mutant human amyloid precursor protein (APP) leads to the formation of plaques in the frontal cortex by 4 months of age (47) . At 6 months of age, both models exhibited elevated levels of monomeric and high molecular weight (HMW) species of aSyn in detergent-insoluble brain fractions (Fig. 6A and B) . This change correlated with an apparent accumulation of Rab4 and HMW forms of Rab5, but no alterations in the mobility or levels of EEA1.
To validate these observations, we analyzed Rab5, Rab4 and EEA1 levels in two subgroups of human amyloidopathies,
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Human including DLB/PD and AD. Consistent with the mouse studies, detergent-insoluble HMW species of aSyn accumulated in strict synucleinopathies and AD cases compared with age-matched control subjects ( Fig. 6C and D) . In addition, levels of Rab5, but not Rab4 or EEA1, were markedly elevated in DLB/PD and AD relative to controls. As in the mice models, Rab5 exhibited a mobility shift to HMW forms in all the amyloidopathy cases studied, whereas the mobility of Rab4 or EEA1 was unchanged. Although the functional significance of the Rab5 mobility shift is unknown, the co-localization of aSyn granular aggregates with enlarged endosomes and the correlation between accumulation of aSyn HMW species and Rab5 suggest a causative role for aSyn in EE dysfunction. Consistent with this hypothesis, using small hairpin RNA-mediated gene knock down and overexpression studies, we recently found that stx7, Vps24, Vps28, Vps34, Vps45 and Vps52, proteins involved in endosomal transport, modulate aSyn toxicity in a dopaminergic SH-SY5Y neuroblastoma cell line and in primary neurons (Lee et al., manuscript in review).
To investigate a possible involvement of mammalian CKI proteins in the pathogenesis of synucleinopathies in vivo, we studied the subcellular localization of CKId, involved in vesicle transport (48, 49) , in brain sections from aSyn tg mice and human DLB/PD (Fig. 7) . As expected, CKId localized predominantly to the cell periphery in cortical neurons from non-tg animals. In contrast, CKId co-localized with aSyn inclusions in tg animals. Importantly, this association was also found in neuronal inclusions in human DLB/PD, consistent with the notion that CKId may be sequestered by/ recruited to aSyn inclusions in synucleinopathies.
Elevated levels of CK1d mRNA have been detected in AD brains (50) , suggesting that upregulation of CK1d may be a Figure 5 . Abnormal endosome morphology in aSyn tg mice and in synucleinopathy brains. Abnormally enlarged Rab5-positive endosomes co-localize with granular inclusions of aSyn and accumulate in the vicinity of aSyn inclusions in aSyn tg mice and human DLB/PD. Cortical sections from aSyn tg mice or DLB/PD cases were double-labeled with antibodies against aSyn and Rab5 and detected with Tyramide Red or FITC-conjugated secondary antibodies, respectively. Images of non-tg animals and control (Ct) subjects are included for reference. Arrows indicate the Rab5-positive compartments. Scale bar, 10 mm. Figure 6 . Analysis of levels of the EE markers Rab5, Rab4 and EEA1, and of mammalian CK1d in mice models and human synucleinopathies. Brain particulate fractions from aSyn tg, APP tg or non-tg mice (A and B) or from human DLB/PD or AD patients or control (Ct) subjects (C and D) were analyzed by western blot with the indicated antibodies. Arrowheads indicate HMW forms of Rab5.
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Human Molecular Genetics, 2012, Vol. 21, No. 11 compensatory response in AD. To investigate whether CK1d is upregulated in synucleinopathies, we analyzed the levels of CK1d by western blot in brains from aSyn and APP tg mice and human DLB/PD and AD cases ( Fig. 6B and D) . We did not detect any significant changes in the levels of CK1d in mice models or human synucleinopathies, indicating that CK1d is not upregulated in response to aSyn accumulation. CKId levels were also apparently unchanged in AD cases, suggesting that the observed mRNA upregulation in AD may not lead to increased CK1d synthesis, or that the upregulation is tissue-specific and undetectable in whole-brain homogenates.
DISCUSSION
A number of recent studies have shown that aSyn overexpression causes vesicle trafficking defects in a wide variety of model systems (7-10,12,13,15,17) by perturbing SNARE function (11, 51, 52) . In yeast, an early effect of expressing aSyn by a strong galactose-inducible system is an ER-to-Golgi block that precedes a global trafficking failure (12, 13) . This trafficking collapse is accompanied by the formation of aSyn-positive vesicular clusters that co-localize with protein markers of several trafficking routes, including ER-to-Golgi, intra-Golgi, Golgi-to-PM, EE-to-LE, and LE-to-vacuole (13, 15) . The presence of endosome-to-Golgi markers in the clusters is controversial since Gitler et al.
(13) detected Ypt6, but Soper et al. (15) failed to detect Vps17 or Vps29. Importantly, the Rab GTPase Ypt1 and the SNARE Ykt6, involved in ER-to-Golgi vesicle-mediated transport, suppress aSyn-induced trafficking defects (11) (12) (13) .
In this study, we present evidence of the steady-state impairment of late-exocytic, early-endocytic and/or recycling trafficking by constitutive expression of aSyn in yeast from the GPD1 promoter. In agreement with previous studies, we observed that trafficking defects coincide with an accumulation of aSyn-positive vesicles that originate in the vicinity of the cell surface and progressively expand toward the cell interior. The vesicles co-label with Snc1, an exocytic SNARE that is targeted to the PM and subsequently internalized and recycled for re-use via EE and the Golgi, implying that at least some of the vesicles originate in the Golgi or the PM. We propose that, in our system, aSyn blocks a trafficking step that follows vesicle budding from the Golgi or the PM and precedes fusion to target membranes. However, we cannot exclude the possibility that the observed vesicles constitute a cellular response to cope with the aSyn overload by compartmentalizing the toxic protein.
In our studies, aSyn did not impair the targeting of a number of protein trafficking markers traversing the ER and the Golgi toward the vacuole, indicating that ER-to-Golgi transport is unaffected in our model. The discrepancy between our findings and previous studies may be reconciled by differences in the expression levels, toxicity and duration of the insult attained by distinct expression systems (53, 54) . Whereas prior studies used a galactose-inducible promoter, our studies used a constitutive promoter to assess the effects of aSyn expression on protein trafficking. Interestingly, in the current study, we show that Ypt1 rescues the mislocalization of GFP-Snc1-Sso1 caused by constitutive aSyn expression. Although it is well established that Ypt1 functions in ER-to-Golgi trafficking, this protein also facilitates the recycling of internalized PM proteins (55) . Therefore, we propose that Ypt1 rescues aSyn toxicity by promoting, at least in part, the recycling of PM proteins. Consistent with this interpretation, Ypt6, which is involved in endosome-to-Golgi and intra-Golgi retrograde transport (56) , was also shown to partially suppress aSyn toxicity (12,13). Thus, although it is conceivable that the trafficking defects that we observed might be secondary to the sustained imposition of the primary ER-to-Golgi block, in our system, aSyn appears to directly impair late-exocytic, early-endocytic and/or recycling trafficking without affecting other pathways.
Our observations contribute to accumulating evidence that trafficking defects are a conserved mechanism of pathogenesis in human synucleinopathies. In yeast, Rab GTPases governing multiple trafficking steps are sequestered by aSyn-induced vesicle clusters (13) . Similarly, in humans, members of the Rab family implicated in exocytosis (Rab3a), endocytosis (Rab5) and polarized traffic (Rab8a) interact aberrantly with aSyn in DLB and co-localize with aSyn glial inclusions in MSA (57-59). Conversely, Rab1 (involved in ER-to-Golgi transport), Rab3a and Rab8a are neuroprotective in cellular and animal models in which aSyn is overexpressed (12, 13) . In catecholaminergic cells, aSyn impairs exocytosis, leading to an accumulation of docked vesicles (9) . Finally, clusters of dense core vesicles have been observed in the perimeter of LBs (15, 60, 61) .
Our study provides evidence of anomalies in endosome morphology and the endocytic Rab5 in pathologic states in vivo. In mouse models and human synucleinopathies, EE are abnormally enlarged in cortical neurons and Rab5 co-localizes with aSyn granular inclusions and accumulates abnormally in detergent-insoluble fractions from brain lysates. Similarly, we observed an increase in the levels of Rab4 in aSyn tg mice, but (62), Rab4 controls the function or formation of endosomes involved in endocytic recycling (63) . In contrast, EEA1 is a Rab5 effector (64) .
Therefore, aSyn appears to alter the function of endocytic Rab GTPases without altering the levels of downstream effectors. In agreement with our observations, inhibition of Rab5 GTPase activity results in the formation of unusually large early endocytic structures (65), a phenotype mimicked by the overexpression of aSyn. These alterations suggest that endocytic trafficking defects might also occur and contribute to neuronal dysfunction in synucleinopathies. In striking similarity to our yeast studies, an RNAi screen in the nematode C. elegans showed that endocytosis-defective mutants potently exacerbate aSyn neurotoxicity (17) . Worms that overexpressed aSyn displayed decreased neurotransmitter release, similar to endocytosis-defective mutants. These authors also reported that the knock down of a CK1 gene enhances aSyn toxicity, and showed that aSyn phosphorylated at S129 accumulated in mutants defective in endocytosis (17) .
In agreement with this model, we found that deletion of YCK1 or YCK2, two redundant kinases of the CKI family that promote the endocytosis and delivery of PM proteins to the vacuole, led to an increase in aSyn toxicity. Interestingly, yck1D cells accumulate cargo normally destined for the vacuole in an endocytic compartment, but do not affect trafficking through the CPY and ALP pathways to the vacuole (37). These results are further supported by our previous studies in which the yeast SNARE Tlg2 was identified as a loss-of-function enhancer of aSyn toxicity (20) . Tlg2 participates in endosome-to-Golgi recycling and is required for targeting Yck2 to the PM (39), suggesting that exacerbation of aSyn toxicity in tlg2D cells might be due, at least in part, to decreased CKI activity at the PM. Although we did not detect any significant increase in trafficking defects upon deletion of YCK1, we observed a reduction in aSyn-induced growth and trafficking defects upon overexpression of YCK1. Although Yck1 contributes modestly to the phosphorylation of aSyn at S129, our results indicate that the attenuation of the toxicity and trafficking defects is not mediated by increased phosphorylation of aSyn. Thus, it is conceivable that CKI activity protects against aSyn toxicity by directly promoting PM endocytosis. This hypothesis is consistent with the observation that knocking down the C. elegans YCK1 ortholog csnk-1 by RNAi causes synaptic deficits selectively in aSyn tg worms (17) .
The function of S129 phosphorylation in physiologic and pathologic conditions is unclear. Although only a small fraction of aSyn is phosphorylated in the healthy brain, aSyn is hyperphosphorylated at S129 in pathologic lesions (21, 22, 66) . However, the relevance of S129 phosphorylation to disease pathogenesis is unknown since conflicting observations have been reported. Mimicking phosphorylation has been shown to be neuroprotective (31) or innocuous (29, 32) in rats, but detrimental in Drosophila (30), and SH-SY5Y and oligodendroglial cells (41, 42) . We showed that, in yeast, the effect of S129 phosphorylation on aSyn toxicity is exquisitely dependent on genetic context; although blocking S129 phosphorylation is innocuous in BY4741-derived yeast strains, this markedly increased the toxicity and trafficking defects caused by aSyn in W303-1A-derived strains, supporting a protective role for phosphorylation in specific genetic contexts. Interestingly, W303-1A carries a mutation in the YBP1 gene that decreases oxidative stress responses and increases the sensitivity to oxidative stress. This genetic variability could contribute to the differential sensitivity between the two strain backgrounds to S129A aSyn. Consistent with this hypothesis, aSyn causes oxidative stress and ROS accumulation and increases the vulnerability of yeast to hydrogen peroxide (16, 67) . Conversely, antioxidants and genes involved in the stress response suppress aSyn toxicity in yeast (18, 68) .
Taken together, our studies indicate that aSyn toxicity is linked to trafficking defects and that this phenotype is modulated by phosphorylation-dependent and -independent pathways. For example, the attenuation of toxicity and trafficking defects by YCK1 appears to be uncoupled from S129 phosphorylation. However, the relative contribution of each pathway to aSyn toxicity appears to be dependent on the genetic landscape of the cell.
A previous study by Zabrocki et al. (14) showed that Yck1, Yck2, Yck3 and CKII phosphorylate aSyn at S129. However, although deletion of YCK1 and YCK2 modestly alleviated an aSyn-induced growth defect and stabilized aSyn at the PM, deletion of YCK3 and the four subunits of CKII (CKA1, CKA2, CKB1 and CKB2) exacerbated the growth defect and resulted in aSyn accumulation in intracellular compartments. The latter observation is consistent with the genetic contextdependent enhancement of aSyn toxicity and inclusion formation by the S129A allele we report in this study. Therefore, despite some discrepancies regarding the effects of CKs on aSyn toxicity, the general conclusion arising from both studies is that impairment of endocytic trafficking can at least partially account for increased aSyn toxicity.
There is substantial evidence that mammalian CKs phosphorylate aSyn at S129 in cultured cells and in vivo (22 -24) . In neurons, a number of mammalian CKI isoforms associate with synaptic vesicles, and the phosphorylation of CKI substrates is thought to regulate synaptic vesicle trafficking and neurotransmission. Mammalian CK substrates include proteins implicated in synaptic vesicle formation (AP-3 adaptor complex) (69), docking and fusion (p65) (70) and exocytosis (synaptotagmin I) (71) , and in the storage of neurotransmitters (VMAT2) (72) . Interestingly, some CKI mRNA isoforms (a, d and 1, but especially d) are dramatically upregulated in the hippocampus and associated with tau-containing neurofibrillary tangles in AD and other dementias (50) . Here, we describe for the first time the co-localization of CKId with LBs in DLB/PD, suggesting that CKId may be sequestered in a manner that might prevent proper phosphorylation of its canonical substrates in synucleinopathies.
Based on our observations and previous studies, we have generated a model to describe the cascade of pathogenic events that lead to neuronal dysfunction and death in synucleinopathies (Fig. 8) . As aSyn is normally a synaptic vesicle-associated protein, we hypothesize that, under physiologic conditions, CKId regulates neurotransmission by
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phosphorylating synaptic proteins, potentially including aSyn. Under pathologic conditions, the progressive accumulation of aSyn may lead to sequestration of Rab GTPases and deficits in vesicular endocytic/exocytic/recycling trafficking that ultimately impair neurotransmitter release. We speculate that when all binding sites in synaptic vesicles are saturated, excess aSyn may associate with other compartments, including endosomes, leading to sustained defects in synaptic vesicle homeostasis and neurotransmission. CKId-dependent phosphorylation of vesicular substrates, including aSyn, may play a protective role by attenuating trafficking defects and stabilizing synaptic transmission. In addition, excess aSyn deposited in LBs may irreversibly sequester CKId and other vesicle-associated proteins, resulting in the loss of CKId activity and reduced protection against these defects. In summary, our study provides additional evidence that vesicular trafficking defects involving endocytosis and exocytosis and CKId dysfunction may be relevant for the pathogenesis of synucleinopathies.
MATERIALS AND METHODS
Plasmids
Plasmids p426GPDaSyn(WT)GFP, p426GALaSyn(WT)GFP, pGS416 (GFP-SNC1), pGSSO416 (GFP-SNC1-SSO1), pGNS416 (GFP-NYV1-SSO1), pPEP416 (GFP-PEP12), pPHM5 (GFP-PHM5) and pSNA3416 (SNA3-GFP) have been described (33) (34) (35) (36) . Plasmid pSTE2416 was created by replacing the SNA3 gene from plasmid pSNA3416 (36) with the STE2 gene as a HindIII-AgeI-digested product of PCR amplification.
Plasmid p8xmycSNC1416 (8xMYC-SNC1) was created by replacing the GFP gene from plasmid pGS416 with the 8xMYC sequence as a HindIII -EcoRI-digested product of PCR amplification. Plasmid p8xmycSNC1406 was then created by subcloning the TPI1pr-8xMYC-SNC1 fusion from plasmid p8xmycSNC1416 into the XhoI and BamHI sites of the pRS406 integrating vector (73) . p8xmycSNC1406 was linearized with EcoRV for integration.
Plasmid pmCheSSO416 (mCherry-SNC1-SSO1) was created by replacing the GFP tag from plasmid pGSSO416 with the mCherry gene from plasmid pmCheV5ATG8406 (74) as an XhoI-EcoRI fragment. Plasmid pmCheSSO415 was created by subcloning the TPI1pr-mCherry-SNC1-SSO1 fusion from plasmid pmCheSSO416 into the XhoI and SacI sites of the plasmid p415TEF (54) .
Plasmid p423GPDaSYN(WT)GFP was created by subcloning the SNCA(WT)-GFP fusion from plasmid p426GALa SYN(WT)GFP into the SpeI and XhoI sites of plasmid p423GPD (54) .
Plasmid p423GPDaSYN(WT) was created by subcloning SNCA(WT) from plasmid p426GPDaSYN(WT)GFP into the SacI and XhoI sites of p423GPD (54) .
Plasmids p426GALaSYN(S129A)GFP and p426GALa Syn(S129E)GFP were created by recombining PCR-amplified SNCA(S129A) and SNCA(S129A) (kindly provided by Dr Robert Edwards, UCSF) into BamHI-linearized p426GALa SYN(WT)GFP. Plasmids pRS304aSYN(WT)GFP, pRS304a SYN(S129A)GFP, pRS304aSYN(S129E)GFP, pRS306aSYN (WT)GFP, pRS306aSYN(S129A)GFP, pRS306aSYN (S129E)GFP were then created by subcloning the GAL1pr-SNCA(WT, S129A and S129E)-GFP fusions from the p426GAL-derived plasmids into the SacI and KpnI sites of the integrating vectors pRS304 and pRS306 (73) . Plasmids pRS304(MCS-) and pRS306(MCS-), lacking the multiple cloning site, were created by digesting pRS304 and pRS306 with SacI and KpnI, blunting the ends with DNA Polymerase I, Large (Klenow) Fragment (New England Biolabs) and re-circularizing the plasmids. pRS304-and pRS306-derived plasmids were linearized with EcoRV for integration into the W303-1A strain.
Plasmids pRS405TRP1aSYN(WT)GFP, pRS405TRP1aSYN (S129A)GFP and pRS405TRP1aSYN(S129E)GFP were generated by sequential insertion of the GAL1pr-SNCA(WT, S129A and S129E)-GFP fusions from the p426GAL-derived plasmids into the SacI and KpnI sites of the integrating vector pRS405, followed by insertion of the first and the last 300 bp of the TRP1 ORF in inverted order (3 ′ 5 ′ ) separated by an XmaI site into the SacI site of plasmid pRS405 for gamma integration into the TRP1 locus. Plasmid Figure 8 . A model depicting how aSyn accumulation may cause neurotransmission defects in PD. We hypothesize that, under normal conditions, CKI regulates aSyn function and, possibly, association with synaptic vesicles and neurotransmitter release by phosphorylating synaptic proteins, including aSyn at S129. Under pathologic conditions in which aSyn accumulates and synaptic trafficking and neurotransmission are compromised, CKI may play a protective role in attenuating vesicular trafficking defects and restoring synaptic transmission. However, when all binding sites in synaptic vesicles are saturated, excess aSyn may associate with other compartments, such as endosomes, leading to abnormally enlarged endosomes and defects in synaptic vesicle homeostasis and neurotransmission. In addition, excess aSyn may form insoluble fibrillar deposits that sequester CKI, depleting CKI activity and enhancing synaptic defects. Red crosses indicate possible trafficking steps blocked by aSyn.
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was generated by removing the GAL1pr-SNCA(WT, S129A and S129E)-GFP insert within the SpeI and XhoI sites, blunting the ends with DNA Polymerase I, Large (Klenow) Fragment (New England Biolabs) and re-circularizing the plasmids.
Plasmids pRS406PDR1aSYN(WT)GFP, pRS406PDR1a SYN(S129A)GFP and pRS406PDR1aSYN(S129E)GFP were generated by sequential insertion of the GAL1pr-SNCA(WT, S129A and S129E)-GFP fusions from the p426GAL-derived plasmids into the SacI and KpnI sites of the integrating vector pRS406, followed by insertion of the first and the last 300 bp of the PDR1 ORF in inverted order (3 ′ 5 ′ ) separated by an MfeI site into the SacI site of plasmid pRS406 for gamma integration into the PDR1 locus. Plasmid pRS406PDR13 ′ 5 ′ was generated by removing the GAL1pr-SNCA(WT, S129A and S129E)-GFP insert within the AgeI and XhoI sites, blunting the ends with DNA Polymerase I, Large (Klenow) Fragment (New England Biolabs) and re-circularizing the plasmids.
pRS405-and pRS406-derived plasmids were linearized with XmaI and MfeI, respectively, for integration into the Y5563 strain.
Plasmids p425GALYPT1 and p425GALYCK1 were created by subcloning YPT1 and YCK1 from the Yeast ORF collection (Open Biosystems) into p425GAL (53) (Addgene), using Gateway Technology (Invitrogen).
Plasmid p415YCK1 was created by cloning YCK1 with its endogenous promoter into plasmid p415TEF (54) as a SacIBamHI-digested product of PCR amplification from yeast genomic DNA.
Yeast strains and manipulation
The strains used in this study are summarized in Table 1 .
To generate strain VSY1, the GAL1pr-SNCA(WT)-GFP fusion was PCR-amplified from plasmid p426GALa SYN(WT)GFP, and the MX4-NatR cassette was PCR-amplified from plasmid p4339 (kindly provided by Dr Charles Boone, University of Toronto). Primer sequences were designed to enable the merging of both fragments in a third PCR reaction and the site-directed integration of the resulting GAL1pr-SNCA(WT)-GFP-NatR fusion at the ADE2 locus by homologous recombination in the BY4741 strain (75) .
To generate strain VSY2, the GAL1pr-SNCA(WT)-GFP fusion was PCR-amplified from plasmid p426GALa SYN(WT)GFP, and the URA3-MX6 cassette was PCR-amplified from plasmid p4348 (kindly provided by Dr Charles Boone, University of Toronto). Primer sequences were designed to enable the merging of both fragments in a third PCR reaction and the site-directed integration of the resulting GAL1pr-SNCA(WT)-GFP-URA3 fusion at the TRP1 locus by homologous recombination in the Y5563 strain (76) .
To generate strain VSY4, strains VSY1 and VSY2 were crossed. Diploid cells were selected on SD -Ura + G418 (Invitrogen)/ClonNAT (Werner BioAgents) plates and sporulated. Spores were germinated and haploid cells of both mating types were selected in SD -Arg/Lys/Ura + canavanine (Sigma-Aldrich)/thialysine (Sigma-Aldrich)/G418/clonNAT plates. MATa cells were selected by their inability to grow on SD -His plates, and the mating type was subsequently confirmed by mating test.
Strains VSY53-61 were obtained from a cross between strain VSY4 and the corresponding deletion strains.
Strains pdr1D, yck1D, yck2D, tlg2D and spo14D were retrieved from the Yeast MATa Genome Deletion Collection (Open Biosystems).
Strain VSY5 was generated by disruption of the PDR1 gene from strain VSY4 with the kanMX4 cassette obtained by PCR amplification of genomic DNA from strain pdr1D.
Strain VSY24 was generated by disruption of the kanMX4 cassette from strain VSY17 with the LEU2 cassette obtained by PCR amplification from plasmid pRS415.
Strain VSY25 was generated by disruption of the PDR1 gene from strain VSY24 with the kanMX4 cassette obtained by PCR amplification of genomic DNA from strain pdr1D.
Strain FRY346 was generated by integration of EcoRVlinearized p8xmycSNC1406 plasmid in the BY4741 strain.
Strains VSY67 to VSY74 were generated by consecutive integration of EcoRV-linearized pRS306-and pRS304-derived plasmids in the W303-1A strain.
Strains VSY75-78 were generated by disruption of the YCK1 gene from strains VSY71-78 with the kanMX4 cassette obtained by PCR amplification of genomic DNA from strain yck1D.
Strains VSY79-86 were generated by consecutive integration of XmaI-linearized pRS405-derived plasmids, followed by integration of MfeI-linearized, pRS406-derived plasmids in the Y5563 strain.
Strains BY4741 and FRY346 were transformed with the indicated plasmids, using the one-step protocol (43) and cultured in synthetic complete medium without the corresponding nutrients for auxotrophic selection and with the indicated carbon sources.
The integrated strains were transformed using the standard protocol (77) and cultured in rich (YEP) medium with the indicated carbon sources.
Yeast growth curves
The indicated strains were inoculated in triplicate in 100 ml of raffinose-containing medium in 96-well plates and grown for 48 h to the stationary phase. Cultures were then diluted 100-fold in raffinose-and galactose-containing media and incubated at 308C. The OD 600 was recorded at the indicated times. Growth rates were determined as the slope of the growth curves during the logarithmic phase.
Pharmacologic inhibition of CKI activity
For the CKI inhibitor studies, strains pdr1D (0c aSyn in pdr1D), VSY5 (2c aSyn in pdr1D) and VSY24 (2c aSyn in pdr1D yck1D) were grown in raffinose-containing medium to the stationary phase, diluted to OD 600 ¼ 0.1 in raffinose-and galactose-containing media and dispensed in 100 ml of aliquots to 96-well plates. Aliquots were treated in triplicate with the indicated concentrations of D4476 (Calbiochem, CA, USA) or vehicle DMSO alone.
Phosphorylation assays
For the time-course experiment, strain VSY4 (2c aSyn in WT) was grown to the logarithmic phase (OD 600 ≈ 0.8) in raffinosecontaining medium, and aSyn expression was induced by adding 0.2% galactose. At the indicated times, 8 ml of aliquots were collected. For protein extraction, cells were collected by centrifugation, washed with water and resuspended in 200 ml of extraction buffer [200 mM Tris, pH 8.0, 150 mM ammonium sulfate, 10% glycerol, 1 mM EDTA, 1 mM microcystin LR, 200 mM activated Na 3 VO 4 and 1× complete protease inhibitor cocktail (Roche)] and 100 ml of acid-washed glass beads (425 -600 mm) (Sigma-Aldrich). Cells were lysed by vortexing two times for 5 min at 48C. Supernatants were separated from cell debris and beads by centrifugation at 5000 r.p.m. for 5 min and then cleared by centrifugation at 13 000 r.p.m. for 30 min. The soluble fractions (supernatant) were separated by SDS -PAGE and proteins analyzed by immunoblot with mouse anti-aSyn (1:20 000) (BD Transduction Laboratories) and anti-S129 phospho-specific antibodies (1:20 000) (JH22.11A5, Elan Pharmaceuticals).
For comparison of aSyn phosphorylation levels in different deletion backgrounds, strains VSY4, VSY17, VSY58 and VSY60 were grown to the logarithmic phase (OD 600 ≈ 0.8) in raffinose-containing medium, and aSyn expression was induced by adding 0.2% galactose for 1 h. Samples were treated as described before, and soluble fractions were analyzed by western blot. Band densities were quantified with ImageQuant 5.2 (Molecular Dynamics).
To assess aSyn phosphorylation in YCK1-overexpressing cells, the indicated strains were grown for 12 h to the logarithmic phase in raffinose-containing medium and induced with 2% galactose. At 5.5 and 11 h, 10 ml of aliquots were collected. When indicated, cultures were treated with 500 nM microcystin and 200 mM cell-permeable Na 3 VO 4 for 15 min prior to cell harvesting. Samples were analyzed as described before.
Analysis of aSyn levels in yeast
Strains VSY67-74 and VSY79-86 were grown to the logarithmic phase in raffinose-containing medium and induced with 2% galactose for 8 h. Samples were processed and analyzed by western immunoblot as described before.
Analysis of aSyn, Rab5, Rab4, EEA1 and CK1d cellular levels Brain homogenates were solubilized in lysis buffer (1% Triton X-100, 10% glycerol, 50 mM HEPES, pH 7.4, 140 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , 20 mM b-glycerophosphate and proteinase inhibitor cocktails) and separated into cytosolic and particulate fractions by centrifugation. Twenty milligrams of the particulate fractions were resolved by SDS-PAGE and blotted onto membranes before be decorated with rabbit polyclonal anti-aSyn (Chemicon), mouse monoclonal anti-Rab5 (BD Transduction Laboratories), mouse anti-human EEA1 (BD Transduction Laboratories), mouse anti-human Rab4 (BD Transduction Laboratories), goat anti-CK1d (C-18) (Santa Cruz Biotechnology) and mouse monoclonal anti-actin (Chemicon).
Mouse models
For this study, 12 heterozygous tg, 6-month-old mice expressing human aSyn under the regulatory control of the plateletderived growth factor-b promoter (Line D) (46) and 12 littermate non-tg, age-matched controls were used. These animals were selected because they display abnormal accumulation of detergent-insoluble aSyn, develop cytoplasmic aSyn-immunoreactive inclusion-like structures in the brain and display neurodegenerative and motor deficits that mimic certain aspects of DLB/PD (46, (78) (79) (80) . Comparisons of the patterns of aSyn and Rab5 distribution were performed with six tg 6-month-old mice that mimic AD-like pathology by expressing the human mutant APP (line 41) under the thy1 promoter (47) .
Human cases and neuropathologic evaluation
This study examined a total of 18 subjects (Table 2) , including 8 cases of DLB/PD, 6 cases of Alzheimer's disease (AD) and 4 non-demented controls. Autopsy material was obtained from patients studied neurologically and psychometrically at the Alzheimer Disease Research Center/University of California, San Diego (ADRC/UCSD). For each case, paraffin sections from 10% buffered formalin-fixed neocortical, limbic system and sub-cortical material stained with hematoxylin and eosin (H&E) and thioflavin-S were used for routine neuropathologic analysis (81, 82) that included the Braak stage (83). The diagnosis of DLB/PD was based on the clinical presentation of dementia, followed by parkinsonism and the pathologic findings of LBs in the locus coeruleus, SN or nucleus basalis of Meynert, as well as in cortical and subcortical regions. LBs were detected using H&E anti-ubiquitin and anti aSyn antibodies as recommended by the Consortium on DLB criteria for a pathologic diagnosis of DLB/PD (84) . In addition to the presence of LBs, the great majority of these cases 
Fluorescence microscopy of yeast
For the S129 mutagenesis study, strains VSY67-74 were grown to the stationary phase at 308C in raffinose-containing medium and diluted 100-fold in galactose-containing medium. Cells were induced for 16 h, mounted and sealed as described.
For the trafficking studies, strain BY4741 co-transformed with plasmids p423GPDaSYN(WT) or p423GPF and pGS416 (GFP-SNC1), pGSSO416 (GFP-SNC1-SSO1), pGNS416 (GFP-NYV1-SSO1), pPEP416 (GFP-PEP12), pPHM5 (GFP-PHM5), pSNA3416 (SNA3-GFP) or pSTE2416 (GFP-STE2) was grown for 12 h to the logarithmic phase at 308C in glucose-containing medium and mounted as described. Strains BY4741, yck1D, VSY4 and VSY17 transformed with plasmid pmCheSSO416 (mCherry-SNC1-SSO1) were grown for 12 h to the logarithmic phase at 308C in galactose-containing medium and mounted as described.
For FM 4-64 labeling, the indicated strains were grown for 12 h in medium containing glucose [deletion and temperaturesensitive mutant strains transformed with plasmid pGSSO416 (GFP-SNC1-SSO1)] or galactose (strains VSY71-74) at 308C (deletion strains and VSY71-74) or RT (temperature-sensitive strains). A total of 0.16 culture ODs were centrifuged and resuspended in 40 ml of medium containing 40 mM FM 4-64 to a final OD 600 of 4.0. Cells were pulsed with the dye for 15 min, washed with 1 ml of H 2 O, resuspended in 0.5 ml of unlabeled medium and incubated for 1 h to let the dye internalize. The deletion and VSY71-74 strains were labeled at 308C, whereas the temperature-sensitive strains were preincubated at 378C or RT for 30 min prior to the FM 4-64 pulse and kept at the same temperature throughout all the steps for imaging.
For the rescue studies, strain BY4741 co-transformed with plasmids p423GPDaSYN(WT) or p423GPF alone, and pGSSO416 (GFP-SNC1-SSO1), was transformed with plasmids p425GALYPT1, p425GALYCK1 or left untransformed (no plasmid). Cells were grown in glucose-containing medium at 308C to the stationary phase and diluted down 20-fold in galactose-containing medium. Cultures were induced for 16 h and prepared for imaging as described.
For the mutagenesis, trafficking, rescue and FM 4-64 studies, cells were imaged with a Nikon Plan Apo VC 100× (N.A. 1.4) objective on a spinning disc confocal microscope (Nikon) and images were acquired with a Cascade II digital camera (Photometrics), using Micro-Manager 1.3 (University of California, San Francisco).
IEM of yeast
For single-labeling, strain BY4741 transformed with the plasmid p426GALaSyn(WT)GFP was grown at 308C in glucose-containing medium to the early logarithmic phase, washed with water, resuspended in galactose-containing medium and incubated for 6 or 12 h. For double-labeling, strain FRY346 transformed with plasmid p423GPDa SYN(WT)GFP was grown for 12 h at 308C in glucosecontaining medium to the logarithmic phase. In both cases, cells were fixed with 2% glutaraldehyde -0.2% para-formaldehyde and prepared for the Tokuyasu cryosectioning procedure according to a protocol optimized for Saccharomyces cerevisiae (85) . Ultrathin sections were incubated first with antibodies recognizing the tags and subsequently with protein A-gold conjugates (86) . After standard staining with uranyl and embedding in methylcellulose, sections were visualized in a JEOL 1010 electron microscope, and images were recorded on Kodak 4489 sheet films.
For single-labeling, a polyclonal anti-GFP antiserum was used (Abcam). For double-labeling, a monoclonal anti-myc antibody (Santa Cruz Biotechnology) and the same anti-GFP antiserum were used. Untransformed cells were treated in the same way and used as background controls.
Immunofluorescence of mammalian cells
For the co-localization studies, sections from the temporal cortex of DLB/PD and control cases and from aSyn tg and non-tg mice were used. Free-floating 40 mm thick vibratome sections were washed with Tris-buffered saline (TBS, pH 7.4), pre-treated in 3% H 2 O 2 and blocked with 10% serum (Vector), 3% bovine serum albumin (Sigma-Aldrich) and 0.2% gelatin in TBS-Tx. Double-immunofluorescence analyses were performed utilizing the Tyramide Signal Amplification TM -Direct (Red) system (NEN Life Sciences). Specificity of this system was tested by deleting each primary antibody. For the Rab5 studies, sections were double-labeled with monoclonal antibodies against aSyn (1:20 000) (Cell Signaling) and Rab5 (1:75) (Vector) and detected with Tyramide Red and fluorescein isothiocyanate (FITC)-conjugated secondary antibodies (1:75) (Vector), respectively. For the CKId studies, sections were double-labeled with the polyclonal antibodies against aSyn (1:200) (Chemicon) and CKId (C-18) (Santa Cruz Biotechnology) and detected with FITC and Tyramid Redconjugated secondary antibodies (1:75) (Vector), respectively. Sections were imaged with a Zeiss 63× (N.A. 1.4) objective on an Axiovert 35 microscope (Zeiss) with an attached MRC1024 laser scanning confocal microscope system (BioRad). All sections were processed simultaneously under the same conditions and experiments were performed twice for reproducibility.
Statistical analyses
Statistical analysis was performed using Prism 5 (GraphPad Software). Student's t-test was run for pairwise comparisons between groups at a single condition, and ANOVA for repetitive measurements was run for pairwise comparisons between groups throughout multiple treatments. Significance P-values were * P , 0.05, * * P , 0.01 and * * * P , 0.001.
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